

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011

NCT07295496

Status	RECRUITING
Phase	Phase 1
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Enrollment	64 participants

Key Eligibility Criteria

Inclusion (3)

- Age ≥18 years of age, male or female;
- Body mass index (BMI) 18-26 kg/m² (inclusive) for Part A healthy subjects and BMI 18-40 kg/m² (inclusive) for Part B acute gout flare subjects; Part B acute gout flare subjects also needed to meet the following criteria
- Meet ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout;

Exclusion (13)

- Subjects meeting any of the following criteria are not eligible to attend this clinical study:
- Difficulties in venous blood collection or a history of dizziness when encountering blood or needles;
- Have received an experimental agent within 1 month or 5 times half-life (whichever is longer) prior;
- Have live or attenuated vaccination in the 3 months before randomization or plan to receive that during this trial;
- Blood donation or blood loss of more than 400 mL within 8 weeks before the screening;
- ... and 8 more (see full listing online)

Locations (1 total)

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China